Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1998 Nov;44:2444–2449.

Guidelines for using insulin lispro.

E L Toth 1, K C Lee 1
PMCID: PMC2277950  PMID: 9839062

Abstract

OBJECTIVE: To review the best evidence-based literature on the insulin analogue, lispro insulin, and to provide guidelines for its use. QUALITY OF EVIDENCE: Using the MeSH terms, lispro and insulin analogues, we searched PubMed, Current Contents, MEDLINE, and EMBASE from January 1986 to July 1998 and selected 42 articles out of 97 for high quality and relevance to family medicine. Twenty-eight were randomized controlled trials, but only two studies were blinded because lispro and regular insulin have different optimal times of administration. MAIN MESSAGE: The new insulin analogue, lispro, produces a much more rapid, higher, and shorter-lasting peak level of insulin than regular human insulin, thus mimicking physiologic secretion of insulin more closely. This allows insulin administration just before or just after meals and means patients can manage with fewer snacks. Lispro controls postprandial blood glucose levels better and does not cause hypoglycemia. Although most older studies showed no change in glycosylated hemoglobin (HbA1c) levels, a few recent studies involving refinements, such as continuous subcutaneous insulin infusion or basal insulin to reduce preprandial glucose levels, have found small but significant improvements. Insulin lispro has also been used successfully in cases of insulin resistance and insulin allergy. CONCLUSIONS: Lispro is a useful addition for motivated diabetic patients who like to achieve better control of HbA1c without increased hypoglycemia and to match mealtime insulin injections with diet, exercise, and various lifestyles.

Full text

PDF
2444

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. H., Jr, Brunelle R. L., Keohane P., Koivisto V. A., Trautmann M. E., Vignati L., DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997 Jun 9;157(11):1249–1255. [PubMed] [Google Scholar]
  2. Anderson J. H., Jr, Brunelle R. L., Koivisto V. A., Pfützner A., Trautmann M. E., Vignati L., DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997 Feb;46(2):265–270. doi: 10.2337/diab.46.2.265. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. H., Jr, Brunelle R. L., Koivisto V. A., Trautmann M. E., Vignati L., DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997 Jan-Feb;19(1):62–72. doi: 10.1016/s0149-2918(97)80073-2. [DOI] [PubMed] [Google Scholar]
  4. Barnett A. H., Owens D. R. Insulin analogues. Lancet. 1997 Jan 4;349(9044):47–51. doi: 10.1016/S0140-6736(96)06032-1. [DOI] [PubMed] [Google Scholar]
  5. Berger M., Heinemann L. Are presently available insulin analogues clinically beneficial? Diabetologia. 1997 Jul;40 (Suppl 2):S91–S96. doi: 10.1007/s001250051416. [DOI] [PubMed] [Google Scholar]
  6. Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984 Mar-Apr;7(2):188–199. doi: 10.2337/diacare.7.2.188. [DOI] [PubMed] [Google Scholar]
  7. Brange J., Owens D. R., Kang S., Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990 Sep;13(9):923–954. doi: 10.2337/diacare.13.9.923. [DOI] [PubMed] [Google Scholar]
  8. Burge M. R., Castillo K. R., Schade D. S. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care. 1997 Feb;20(2):152–155. doi: 10.2337/diacare.20.2.152. [DOI] [PubMed] [Google Scholar]
  9. Burge M. R., Waters D. L., Holcombe J. H., Schade D. S. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997 Mar;82(3):920–924. doi: 10.1210/jcem.82.3.3808. [DOI] [PubMed] [Google Scholar]
  10. Demirdjian S., Bardin C., Savin S., Zirinis P., Chast F., Slama G., Sélam J. L. Lispro insulin is suitable for external pumps but not for implantable pumps. Diabetes Care. 1998 May;21(5):867–868. doi: 10.2337/diacare.21.5.867. [DOI] [PubMed] [Google Scholar]
  11. Diamond T., Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med. 1997 Oct 2;337(14):1009–1010. doi: 10.1056/NEJM199710023371414. [DOI] [PubMed] [Google Scholar]
  12. Ebeling P., Jansson P. A., Smith U., Lalli C., Bolli G. B., Koivisto V. A. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care. 1997 Aug;20(8):1287–1289. doi: 10.2337/diacare.20.8.1287. [DOI] [PubMed] [Google Scholar]
  13. Fineberg N. S., Fineberg S. E., Anderson J. H., Birkett M. A., Gibson R. G., Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 1996 Dec;45(12):1750–1754. doi: 10.2337/diab.45.12.1750. [DOI] [PubMed] [Google Scholar]
  14. Garg S. K., Carmain J. A., Braddy K. C., Anderson J. H., Vignati L., Jennings M. K., Chase H. P. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med. 1996 Jan;13(1):47–52. doi: 10.1002/(SICI)1096-9136(199601)13:1<47::AID-DIA999>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  15. Heinemann L., Heise T., Wahl L. C., Trautmann M. E., Ampudia J., Starke A. A., Berger M. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996 Jul;13(7):625–629. doi: 10.1002/(SICI)1096-9136(199607)13:7<625::AID-DIA134>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  16. Henrichs H. R., Unger H., Trautmann M. E., Pfützner A. Severe insulin resistance treated with insulin lispro. Lancet. 1996 Nov 2;348(9036):1248–1248. doi: 10.1016/S0140-6736(05)65529-8. [DOI] [PubMed] [Google Scholar]
  17. Holleman F., Hoekstra J. B. Insulin lispro. N Engl J Med. 1997 Jul 17;337(3):176–183. doi: 10.1056/NEJM199707173370307. [DOI] [PubMed] [Google Scholar]
  18. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J. H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care. 1997 Dec;20(12):1827–1832. doi: 10.2337/diacare.20.12.1827. [DOI] [PubMed] [Google Scholar]
  19. Holleman F., van den Brand J. J., Hoven R. A., van der Linden J. M., van der Tweel I., Hoekstra J. B., Erkelens D. W. Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care. 1996 Dec;19(12):1426–1429. doi: 10.2337/diacare.19.12.1426. [DOI] [PubMed] [Google Scholar]
  20. Howey D. C., Bowsher R. R., Brunelle R. L., Woodworth J. R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994 Mar;43(3):396–402. doi: 10.2337/diab.43.3.396. [DOI] [PubMed] [Google Scholar]
  21. Jacobs M. A., Keulen E. T., Kanc K., Casteleijn S., Scheffer P., Devillé W., Heine R. J. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period. Diabetes Care. 1997 Aug;20(8):1279–1286. doi: 10.2337/diacare.20.8.1279. [DOI] [PubMed] [Google Scholar]
  22. Janssen M. M., Casteleijn S., Devillé W., Popp-Snijders C., Roach P., Heine R. J. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care. 1997 Dec;20(12):1870–1873. doi: 10.2337/diacare.20.12.1870. [DOI] [PubMed] [Google Scholar]
  23. Johnson I. S. Authenticity and purity of human insulin (recombinant DNA). Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):4–12. doi: 10.2337/diacare.5.2.s4. [DOI] [PubMed] [Google Scholar]
  24. Kotsanos J. G., Vignati L., Huster W., Andrejasich C., Boggs M. B., Jacobson A. M., Marrero D., Mathias S. D., Patrick D., Zalani S. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care. 1997 Jun;20(6):948–958. doi: 10.2337/diacare.20.6.948. [DOI] [PubMed] [Google Scholar]
  25. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care. 1997 Sep;20(9):1357–1359. doi: 10.2337/diacare.20.9.1357. [DOI] [PubMed] [Google Scholar]
  26. Lahtela J. T., Knip M., Paul R., Antonen J., Salmi J. Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report. Diabetes Care. 1997 Jan;20(1):71–73. doi: 10.2337/diacare.20.1.71. [DOI] [PubMed] [Google Scholar]
  27. Markussen J., Havelund S., Kurtzhals P., Andersen A. S., Halstrøm J., Hasselager E., Larsen U. D., Ribel U., Schäffer L., Vad K. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996 Mar;39(3):281–288. doi: 10.1007/BF00418343. [DOI] [PubMed] [Google Scholar]
  28. McCowen K. C., Garber J. R., Spark R. Elevated serum thyrotropin in thyroxine-treated patients with hypothyroidism given sertraline. N Engl J Med. 1997 Oct 2;337(14):1010–1011. doi: 10.1056/NEJM199710023371415. [DOI] [PubMed] [Google Scholar]
  29. Melki V., Renard E., Lassmann-Vague V., Boivin S., Guerci B., Hanaire-Broutin H., Bringer J., Belicar P., Jeandidier N., Meyer L. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998 Jun;21(6):977–982. doi: 10.2337/diacare.21.6.977. [DOI] [PubMed] [Google Scholar]
  30. Pampanelli S., Torlone E., Ialli C., Del Sindaco P., Ciofetta M., Lepore M., Bartocci L., Brunetti P., Bolli G. B. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care. 1995 Nov;18(11):1452–1459. doi: 10.2337/diacare.18.11.1452. [DOI] [PubMed] [Google Scholar]
  31. Pfützner A., Küstner E., Forst T., Schulze-Schleppinghoff B., Trautmann M. E., Haslbeck M., Schatz H., Beyer J. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes. 1996;104(1):25–30. doi: 10.1055/s-0029-1211418. [DOI] [PubMed] [Google Scholar]
  32. Schernthaner G., Wein W., Sandholzer K., Equiluz-Bruck S., Bates P. C., Birkett M. A. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care. 1998 Apr;21(4):570–573. doi: 10.2337/diacare.21.4.570. [DOI] [PubMed] [Google Scholar]
  33. Skyler J. S., Skyler D. L., Seigler D. E., O'Sullivan M. J. Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. Diabetes Care. 1981 Mar-Apr;4(2):311–318. doi: 10.2337/diacare.4.2.311. [DOI] [PubMed] [Google Scholar]
  34. Strachan M. W., Frier B. M. Optimal time of administration of insulin lispro. Importance of meal composition. Diabetes Care. 1998 Jan;21(1):26–31. doi: 10.2337/diacare.21.1.26. [DOI] [PubMed] [Google Scholar]
  35. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30;329(14):977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  36. Torlone E., Fanelli C., Rambotti A. M., Kassi G., Modarelli F., Di Vincenzo A., Epifano L., Ciofetta M., Pampanelli S., Brunetti P. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia. 1994 Jul;37(7):713–720. doi: 10.1007/BF00417697. [DOI] [PubMed] [Google Scholar]
  37. Torlone E., Pampanelli S., Lalli C., Del Sindaco P., Di Vincenzo A., Rambotti A. M., Modarelli F., Epifano L., Kassi G., Perriello G. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care. 1996 Sep;19(9):945–952. doi: 10.2337/diacare.19.9.945. [DOI] [PubMed] [Google Scholar]
  38. Tuominen J. A., Karonen S. L., Melamies L., Bolli G., Koivisto V. A. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia. 1995 Jan;38(1):106–111. doi: 10.1007/BF02369359. [DOI] [PubMed] [Google Scholar]
  39. Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med. 1989 Aug 10;321(6):363–370. doi: 10.1056/NEJM198908103210605. [DOI] [PubMed] [Google Scholar]
  40. Zinman B., Tildesley H., Chiasson J. L., Tsui E., Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997 Mar;46(3):440–443. doi: 10.2337/diab.46.3.440. [DOI] [PubMed] [Google Scholar]
  41. ter Braak E. W., Woodworth J. R., Bianchi R., Cerimele B., Erkelens D. W., Thijssen J. H., Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996 Dec;19(12):1437–1440. doi: 10.2337/diacare.19.12.1437. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES